U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973811) titled 'ZR-MTX for PIOL Phase II Trial' on May 06.
Brief Summary: This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of ZR-MTX regimen (rituximab, Zanubrutinib and methotrexate) combined with intravitreal methotrexate and followed by minimal residual disease directed Zanubrutinib maintenance in newly-diagnosed primary intraocular lymphoma. Progression-free survival (PFS) of the cohort is the primary endpoint.
Study Start Date: May 10
Study Type: INTERVENTIONAL
Condition:
Primary Intraocular Lymphoma
Intervention:
DRUG: Methotrexate
400ug intravitreal injection every week for 4 ...